Scientists launch 5-year watch on rare genetic Parkinson's to unlock disease secrets
NCT ID NCT07613112
First seen Jun 26, 2026 · Last updated Sep 18, 2026 · Updated 4 times
Summary
This study follows 70 people with PRKN- or PINK1-linked Parkinson's disease, as well as those with typical Parkinson's and healthy volunteers, over 5 years. Researchers will track movement, thinking, and mood symptoms, and collect blood, urine, and optional spinal fluid or muscle samples. The goal is to better understand how these genetic forms of Parkinson's progress, which could help design future treatments.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could reveal how genetic forms of Parkinson's progress, pointing toward better monitoring or future treatments.
- What could go wrong
- This is an observational study, not a treatment trial. It may not lead directly to new therapies, and results may take years to apply.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 70 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2036
An estimate. End dates often move.
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
There will be a total of up to 50 male or female participants 18- 80 years of age and older in 5 cohorts. Target number of completers for each cohort are listed below: - PD mito-biallelic (PD participants carrying two pathogenic variants in PRKN or PINK1): up to 15 - PD mito-monoallelic (PD participants carrying one pathogenic mono-allelic variant in PRKN and/or PINK1): up to 10 - PD idiopathic: up to 5 - Non-manifesting mito (participants who carry one or two pathogenic variants in PRKN and/or PINK1 but do not have a diagnosis of PD): up to 15 - Healthy controls: up to 5
- Ages
-
18 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: To be eligible to participate in this study, an individual must meet all of the following criteria: All participants: * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female between the ages of 18-80 years old * Ability of subject to understand and the willingness to sign an informed consent document * Ability of subject to travel to the NIH Clinical Center Additional inclusion criteria for each cohort as below: PD Mito - Biallelic: * Established clinical diagnosis of Parkinson's disease * Two Pathogenic or likely pathogenic variants in PRKN or PINK1 PD Mito - Monoallelic: * Established clinical diagnosis of Parkinson's disease * One Pathogenic or likely pathogenic variant in PRKN and/or PINK1 Idiopathic Parkinson's Disease (PD): * Established clinical diagnosis of Parkinson's disease * Etiology of PD is idiopathic/sporadic based on investigator determination Non-manifesting mito: * One or two pathogenic or likely pathogenic variant in PRKN and/or PINK1 * Lack of clinical diagnosis of Parkinson's disease * Lack of current or clinically significant neurological disorder (based on investigator determination) Healthy Volunteer -Lack of current or clinically significant neurological disorder (based on investigator determination) EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: All participants: * Symptomatic PD syndromes due to drugs (e.g., metoclopramide, flunarizine, neuroleptics), metabolic disorders (e.g., Wilson's disease hypothyroidism), encephalitis, brain lesion, atypical parkinsonism, other monogenic forms of PD (e.g., GBA1, LRRK2, SNCA, VPS35, CHCHD2, DJ1, ATP13A2) other genetic disorders that may cause parkinsonism (e.g., spinocerebellar ataxia, X-linked dystonia parkinsonism) * Pregnancy at time of study enrollment * Any other reason that, in the opinion of the investigator, would render the participant unsuitable for study enrollment * Unwilling to allow samples or data to be shared with other researchers or institutions. * NIH staff or family members of study team members Healthy Volunteer: -Participants who become pregnant during the study will be withdrawn from further study procedures at the time pregnancy is identified. Procedural Exclusions: Subjects may still be enrolled if they cannot participate in certain procedures due to not meeting the inclusion requirements for that specific procedure. Subjects who meet exclusion criteria for procedures listed below may still undergo the procedure at a later time if the reason of exclusion is no longer present. Brain MRI: * Contraindications to MRI such as a contraindicated non-removable metal device (i.e., pacemaker, defibrillator, insulin pump, metal clips, non-removable jewelry) * Pregnancy Accelerometer: -Non ambulatory Lumbar puncture procedure: * PT/PTT values that are prolonged greater than or equal to 3 seconds from the upper limit of normal (including treatment with oral and parenteral anticoagulants) * INR greater than 1.4, thrombocytopenia (\<70,000), or abnormal bleeding time or platelet dysfunction * History of a bleeding disorder * Use of anticoagulants or antiplatelets * Pregnancy * History of headache requiring blood patch after a previous LP Needle muscle biopsy: * PT/PTT values that are prolonged greater than or equal to 3 seconds from the upper limit of normal (including treatment with oral and parenteral anticoagulants) * INR greater than 1.4, thrombocytopenia (\<70,000), or abnormal bleeding time or platelet dysfunction * History of a bleeding disorder * Use of anticoagulants or antiplatelets * Pregnancy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Parkinson dis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.